Cipla (EU) Limited, UK, a wholly owned subsidiary of Mumbai-based pharma firm Cipla Limited, has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States (US).

The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions.

Cipla (EU) Limited will secure a 35.2% stake in the joint venture company. By capitalising on Cipla's leadership in product development and commercialisation and aligning with Kemwell's expertise in biologics and Manipal's expertise in healthcare delivery, this strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge cell therapy products to cater to patients globally.

This marks the second joint venture between Cipla and Kemwell Biopharma, following the incorporation of Aspergen Inc., USA in 2022 for the development, manufacturing, and commercialisation of biosimilars for global markets. Aspergen Inc. is actively developing two projects, with several others under evaluation, accelerating Cipla's global lung leadership agenda and strengthening the company's position in the biosimilar market for long-term, diversified growth.